Antitumor effect and immune response induced by local hyperthermia in B16 murine melanoma: Effect of thermal dose

Oncology Letters

Volumn 4, Issue 4, 2012, Pages 711-718

  Li, Dan Ye ^a,b   Tang, Yang Ping ^b,c   Zhao, Ling Yun ^b   Geng, Chuan Ying ^d   Tang, Jin Tian ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b TSINGHUA UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^d CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

B16 melanoma; Immunity response; Local hyperthermia; Lung metastasis; Thermal dose

Indexed keywords

GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; HYPERTHERMIC THERAPY; IMMUNE RESPONSE; LUNG METASTASIS; MALE; MELANOMA B16; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR VOLUME;

EID: 84864709810     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.804     Document Type: Article

References (27)

1. Thompson JF, Scolyer RA and Kefford RF: Cutaneous melanoma. Lancet 365: 687-701, 2005.
2. Sondak VK, Gonzalez RJ and Kudchadkar R: Adjuvant therapy for melanoma: a surgical perspective. Surg Oncol Clin N Am 20: 105-114, 2011.
3. Hong M, Puaux AL, Huang C, Loumagne L, Tow C, Abastado J, et al: Chemot herapy i nduces i nt rat umora l expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res 71: 6997-7009, 2011.
4. McLoughlin JM, Zager JS, Sondak VK and Berk LB: Treatment options for limited or symptomatic metastatic melanoma. Cancer Control 15: 239-247, 2008.
5. Chicheł A, Skowronek J, Kubaszewska M and Kanikowski M: Hyperthermia - description of a method and a review of clinical applications. Rep Pract Oncol Radiother 12: 267-275, 2007.
6. Soares PI, Ferreira IM, Igreja RA, Novo CM and Borges JP: Application of hyperthermia for cancer treatment: recent patents review. Recent Pat Anticancer Drug Discov 7: 64-73, 2012.
7. Pace M, Gattai R, Mascitelli EM and Millanta L: Results of isolated lower limb per fusion for loco-regional advanced / recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases. J Surg Oncol 104: 718-723, 2011.
8. Stojkovic R and Radacic M: Cell killing of melanoma B16 in vivo by hyperthermia and cytotoxins. Int J Hyperther 18: 62-71, 2002.
9. Ito A, Fujioka M, Yoshida T, et al: 4-S-Cysteaminylphenol-loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma. Cancer Sci 98: 424-430, 2007.
10. Haen SP, Pe r ei r a PL, Sa l i h H R, R a m m en s e e HG a nd Gouttefangeas C: More than just tumor destruction: immuno-modulation by thermal ablation of cancer. Clin Dev Immunol 10: 55-74, 2011.
11. Zhou ZX, Yin XY, Lv MD, et al: Homing of dendritic cells injected into the mouse hepatoma after microwave ablation under different temperature. Chinese J Pathophys 22: 355-359, 2006.
12. Paton WDM: Compound 48/80: a potent histamine liberator. Brit J Pharmacol 6: 499-508, 1951.
13. Rothschild AM: Mechanisms of histamine release by compound 48/80. Brit J Pharmacol 38: 253-262, 1970.
14. McLachlan JB, Shelburne CP, Hart JP, et al: Mast cell activators: a new class of highly effective vaccine adjuvants. Nat Med 14: 536-541, 2008.
15. McGowen A L, Hale LP, Shelburne CP, Abraham SN and Staats HF: The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen. Vaccine 27: 3544-3552, 2009.
16. Dayanc BE, Beachy SH, Ostberg JR and Repasky EA: Dissecting the role of hyperthermia in natural killer cell mediated anti-tumor responses. Int J Hyperther 24: 41-56, 2008.
17. Dewey WC: Arrhenius relationships from the molecule and cell to the clinic. Int J Hyperthermia 10: 57-83, 1994.
18. Kayihan E: Biological rationale and clinical experience with hyperthermia. Clin Trials 17: 316-342, 1996.
19. Tanaka K, Ito A, Kobayashi T, et al: Heat immunotherapy using magnetic nanoparticles and dendritic cells for T-lymphoma. J Biosci Bioeng 100: 112-115, 2005.
20. Kidd P: Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 8: 23-46, 2003.
21. Laueroval L, Dusek L, Simickova M, et al: Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and im munotherapy response. Neoplasma 49: 159-166, 2002.
22. Terabe M, Park JM and Berzofsky JA: Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother 53: 79-85, 2004.
23. Romagnani S: The Th1/Th2 paradigm. Immunol Today 18: 3-6, 1997.
24. Sheeja K and Kuttan G: Effect of Andrographis paniculata as an adjuvant in combined chemo-radio and whole body hyper-thermia treatment - a preliminary study. Immunopharmacol Immunotoxicol 30: 181-194, 2008.
25. Den Brok MH, Sutmuller RPM, Van der Voort R, et al: In situ tumor ablation creats an antigen source for the generation of antitumor immunity. Cancer Res 64: 4024-4029, 2004.
26. Jia D, Liu J, Rao W, et al: Inhibition of B16 murine melanoma metastasis and enhancement of immunity by fever-range whole body hyperthermia. Int J Hyperther 27: 275-285, 2011.
27. Morita M, Kuwano H, Araki K, Egashira A, Kawaguchi H, Saeki H, et al: Prognostic significance of lymphocyte infiltration following preoperative chemoradiotherapy and hyperthermia for esophageal cancer. Int J Radiat Oncol Biol Phys 49: 1259-1266, 2001.